Technical Analysis for ALGS - Aligos Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Flat | Flat |
| Historical ALGS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | -0.19% | |
| Bearish Engulfing | Bearish | 0.38% | |
| Fell Below 50 DMA | Bearish | 0.38% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.38% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.38% | |
| Narrow Range Bar | Range Contraction | 0.38% | |
| New Downtrend | Bearish | -0.38% | |
| Crossed Above 50 DMA | Bullish | -0.38% | |
| Outside Day | Range Expansion | -0.38% | |
| Up 3 Days in a Row | Strength | -0.38% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 2% | about 2 hours ago |
| Rose Above 20 DMA | about 3 hours ago |
| 10 DMA Support | about 3 hours ago |
| 50 DMA Support | about 3 hours ago |
| 60 Minute Opening Range Breakout | about 3 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/05/2021
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Alcohol Drug Development Coronavirus Hepatitis B Viruses Steatohepatitis Hepatitis Liver Disease Non Alcoholic Fatty Liver Disease Liver Diseases Viral Diseases Viral Infection Viral Infections Chronic Hepatitis Antiviral Therapies Chronic Hepatitis B
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Alcohol Drug Development Coronavirus Hepatitis B Viruses Steatohepatitis Hepatitis Liver Disease Non Alcoholic Fatty Liver Disease Liver Diseases Viral Diseases Viral Infection Viral Infections Chronic Hepatitis Antiviral Therapies Chronic Hepatitis B
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 37.465 |
| 52 Week Low | 12.82 |
| Average Volume | 238,591 |
| 200-Day Moving Average | 22.92 |
| 50-Day Moving Average | 15.76 |
| 20-Day Moving Average | 16.08 |
| 10-Day Moving Average | 15.84 |
| Average True Range | 0.87 |
| ADX | 25.35 |
| +DI | 12.98 |
| -DI | 23.29 |
| Chandelier Exit (Long, 3 ATRs) | 14.94 |
| Chandelier Exit (Short, 3 ATRs) | 17.10 |
| Upper Bollinger Bands | 17.34 |
| Lower Bollinger Band | 14.82 |
| Percent B (%b) | 0.39 |
| BandWidth | 15.66 |
| MACD Line | -0.15 |
| MACD Signal Line | -0.15 |
| MACD Histogram | -0.0012 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.61 | ||||
| Resistance 3 (R3) | 16.57 | 16.28 | 16.47 | ||
| Resistance 2 (R2) | 16.28 | 16.07 | 16.29 | 16.43 | |
| Resistance 1 (R1) | 16.04 | 15.95 | 16.16 | 16.08 | 16.38 |
| Pivot Point | 15.75 | 15.75 | 15.81 | 15.76 | 15.75 |
| Support 1 (S1) | 15.51 | 15.54 | 15.63 | 15.55 | 15.24 |
| Support 2 (S2) | 15.22 | 15.42 | 15.23 | 15.19 | |
| Support 3 (S3) | 14.98 | 15.22 | 15.15 | ||
| Support 4 (S4) | 15.02 |
